Accepted for Publication: July 14, 2022.
Published Online: October 20, 2022. doi:10.1001/jamaoncol.2022.4457
Corresponding Author: Christian Rolfo, MD, PhD, MBA, Center for Thoracic Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, One Levy Pl, Box 1079, New York, NY 10029 (christian.rolfo@mssm.edu).
Author Contributions: All authors had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Krebs, Malapelle, Paz-Ares, Schuler, Vainer, Yoshino, Rolfo.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Krebs, Malapelle, Schuler, Thomas, Vainer, Yoshino, Rolfo.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Andre, Rolfo.
Administrative, technical, or material support: Malapelle, Paz-Ares.
Supervision: Paz-Ares, Schuler, Rolfo.
Conflict of Interest Disclosures: Dr Krebs reported nonfinancial support and grants from Roche during the conduct of the study; consulting and speaker fees from AstraZeneca, Bayer, Guardant, Janssen, Roche, and Seattle Genetics; travel expenses from BerGenBio, Immutep, and Janssen; institutional funding from AstraZeneca, Bayer, BerGenBio, Blueprint, Carrick, Chugai, Immutep, Janssen, Novartis, Nurix, Relay Therapeutics, Roche, Seattle Genetics, and Turning Point Therapeutics outside the submitted work. Dr Malapelle reported speaking and advisory fees from Boehringer Ingelheim, Roche, Merck Sharp & Dohme, Amgen, Thermo Fisher Scientifics, Eli Lilly, Diaceutics, GlaxoSmithKline, Merck, AstraZeneca, Janssen, Diatech, Novartis, and Hedera, all outside the submitted work. Dr Andre reported grants from Novartis, Daiichi, Roche, Eli Lilly, AstraZeneca, and Pfizer compensated to the hospital, all outside the submitted work. Dr Paz-Ares reported speaking and/or scientific advisory fees from Amgen, AstraZeneca, Pfizer, Bristol Myers Squibb, Roche , Merck Sharp & Dohme, Mirarti, Bayer, Eli Lilly, PharmaMar, Ipsen, Guardant, Merck, and Novartis; grants from Pfizer, Bristol Myers Squibb, AstraZeneca, and PharmaMar; being a cofounder of Altum sequencing; and being a board member of Genómica, all outside the submitted work. Dr Schuler reported scientific consulting and presentation fees from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Merck, Serono, and Novartis; consulting fees from Roche and Sanofi; and grants to the institution from AstraZeneca and Bristol Myers Squibb, outside the submitted work; in addition, Dr Schuler reports a patent for a highly sensitive PCR method for mutation detection issued to the University Duisburg-Essen. Dr Thomas reported grants from Roche, AstraZeneca, Bayer, Amgen, Pfizer, BeiGene, Seattle Genetics, Sun Pharma, and Eisai; and being chief executive officer of Omico, during the conduct of the study. Dr Vainer reported personal fees from Roche, Pfizer, AbbVie, Takeda, Bayer, and AstraZeneca; and nonfinancial support from Bristol Myers Squibb, during the conduct of the study. Dr Yoshino reported personal fees from Chugai, Merck, Bayer, Ono, and Merck Sharp & Dohme; and grants from Merck Sharp & Dohme, Daiichi Sankyo, Ono, Taiho, Amgen, Sanofi, Pfizer, Genomedia, Sysmex, Nippon Boehringer Ingelheim, and Chugai, all outside the submitted work. Dr Rolfo reported advisory board, speaking fees, and nonfinancial medical writing support from Roche and nonfinancial support during the conduct of the study; advisory/committee fees from Bristol Myers Squibb, AstraZeneca, Merck Sharp & Dohme, Pfizer, Mirarti, COR2ED, Daiichi Sankyo, Sanofi, Genzyme-Regeneron, Bayer, and Eisai; grants from the US National Institutes of Health’s SeroNet, the Lung Cancer Research Foundation, and Pfizer; and being on data safety monitoring/advisory boards for EMD, Merck Serono, ISLB president, the International Association for the Study of Lung Cancer, European School of Oncology, European Society for Medical Oncology, editor-in-chief of Critical Reviews in Oncology/Hematology at Elsevier, and former associate editor of ESMO Open, all outside the submitted work. No other disclosures were reported.
Additional Contributions: Research support in the form of third-party medical writing assistance and formatting for this narrative review—furnished by Blair Jarvis, MSc, on behalf of Health Interactions, and Islay Steele, PhD, Health Interactions—was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
7.Metzenmacher
M , Váraljai
R , Hegedüs
B ,
et al. Plasma next generation sequencing and droplet digital-qPCR-based quantification of circulating cell-free RNA for noninvasive early detection of cancer.
Cancers (Basel). 2020;12(2):353. doi:
10.3390/cancers12020353
PubMedGoogle ScholarCrossref 9.Slavin
TP , Banks
KC , Chudova
D ,
et al. Identification of incidental germline mutations in patients with advanced solid tumors who underwent cell-free circulating tumor DNA sequencing.
J Clin Oncol. 2018;36(35):JCO1800328. doi:
10.1200/JCO.18.00328
PubMedGoogle ScholarCrossref 16.Rolfo
C , Cardona
AF , Cristofanilli
M ,
et al; ISLB. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB).
Crit Rev Oncol Hematol. 2020;151:102978. doi:
10.1016/j.critrevonc.2020.102978
PubMedGoogle ScholarCrossref 20.Zugazagoitia
J , Gómez-Rueda
A , Jantus-Lewintre
E ,
et al. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Lung Cancer. 2019;134:72-78. doi:
10.1016/j.lungcan.2019.05.032
PubMedGoogle ScholarCrossref 33.Papaemmanuil
E , Gerstung
M , Malcovati
L ,
et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes.
Blood. 2013;122(22):3616-3627. doi:
10.1182/blood-2013-08-518886
PubMedGoogle ScholarCrossref 34.Xiao
J , Li
W , Huang
Y ,
et al. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
BMC Cancer. 2021;21(1):282. doi:
10.1186/s12885-021-07942-1
PubMedGoogle ScholarCrossref 35.Büttner
R , Gosney
JR , Skov
BG ,
et al. Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer.
J Clin Oncol. 2017;35(34):3867-3876. doi:
10.1200/JCO.2017.74.7642
PubMedGoogle ScholarCrossref 38.Galldiks
N , Kocher
M , Ceccon
G ,
et al. Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression.
Neuro Oncol. 2020;22(1):17-30. doi:
10.1093/neuonc/noz147
PubMedGoogle ScholarCrossref 40.Peters
S , Cho
BC , Reinmuth
N ,
et al. Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): blood and tissue TMB analysis from MYSTIC, a phase III study of first-line durvalumab ± tremelimumab vs chemotherapy.
Cancer Res. 2019:79. doi:
10.1158/1538-7445.AM2019-CT074
Google ScholarCrossref 41.Socinski
M , Velcheti
V , Mekhail
T ,
et al. Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC).
Ann Oncol. 2019;30(suppl 5):851-934. doi:
10.1093/annonc/mdz394.081Google ScholarCrossref 42.Mok
T , Gadgeel
S , Kim
E ,
et al. Blood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC.
Ann Oncol. 2017;28(suppl 5):460-496. doi:
10.1093/annonc/mdx380.084Google ScholarCrossref 43.Woodhouse
R , Li
M , Hughes
J ,
et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
PLoS One. 2020;15(9):e0237802. doi:
10.1371/journal.pone.0237802
PubMedGoogle ScholarCrossref 44.Dziadziuszko
R , Peters
S , Gadgeel
SM ,
et al. Atezolizumab (Atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C.
Ann Oncol. 2021;32(suppl 5):950-951. doi:
10.1016/j.annonc.2021.08.1883
Google ScholarCrossref 48.De Mattia
E , Roncato
R , Palazzari
E , Toffoli
G , Cecchin
E . Germline and somatic pharmacogenomics to refine rectal cancer patients selection for neo-adjuvant chemoradiotherapy.
Front Pharmacol. 2020;11:897. doi:
10.3389/fphar.2020.00897
PubMedGoogle ScholarCrossref 52.Ali
N , Lifford
KJ , Carter
B ,
et al. Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial.
BMJ Open. 2015;5(7):e008254. doi:
10.1136/bmjopen-2015-008254
PubMedGoogle ScholarCrossref 53.Lecomte
T , Berger
A , Zinzindohoué
F ,
et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis.
Int J Cancer. 2002;100(5):542-548. doi:
10.1002/ijc.10526
PubMedGoogle ScholarCrossref 55.Santiago-Walker
A , Gagnon
R , Mazumdar
J ,
et al. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials.
Clin Cancer Res. 2016;22(3):567-574. doi:
10.1158/1078-0432.CCR-15-0321
PubMedGoogle ScholarCrossref 58.Li
S , Lai
H , Liu
J ,
et al Circulating tumor DNA predicts the response and prognosis in patients with early breast cancer receiving neoadjuvant chemotherapy.
JCO Precis Oncol. 2020:4:PO.19.00292. doi:
10.1200/PO.19.00292Google ScholarCrossref 60.Pazdirek
F , Minarik
M , Benesova
L ,
et al. Monitoring of early changes of circulating tumor DNA in the plasma of rectal cancer patients receiving neoadjuvant concomitant chemoradiotherapy: evaluation for prognosis and prediction of therapeutic response.
Front Oncol. 2020;10:1028. doi:
10.3389/fonc.2020.01028
PubMedGoogle ScholarCrossref 62.Radovich
M , Jiang
G , Hancock
BA ,
et al. Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: Preplanned secondary analysis of the BRE12-158 randomized clinical trial.
JAMA Oncol. 2020;6(9):1410-1415. doi:
10.1001/jamaoncol.2020.2295
PubMedGoogle ScholarCrossref 66.Wang
Q-X , Qu
C-H , Gao
Y-H ,
et al. The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers.
Exp Hematol Oncol. 2021;10(1):2. doi:
10.1186/s40164-020-00193-z
PubMedGoogle ScholarCrossref 67.Rosenberg
JE , Gajate
P , Morales-Barrera
R ,
et al. Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study.
J Clin Oncol. 2021;39(15)(suppl). Abstract 4521. doi:
10.1200/JCO.2021.39.15_suppl.4521
Google ScholarCrossref